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Abstract: Chlamydia trachomatis (CT) infection is one of
the most common causes of reproductive tract diseases
and infertility. CT-Hsp60 is synthesized during infection
and is released in the bloodstream. As a consequence,
immune cells will produce anti-CT-Hsp60 antibodies.
Hsp60, a ubiquitous and evolutionarily conserved chaper-
onin, is normally sequestered inside the cell, particularly
into mitochondria. However, upon cell stress, as well as
during carcinogenesis, the chaperonin becomes exposed
on the cell surface (sf-Hsp60) and/or is secreted from cells
into the extracellular space and circulation. Reports in the
literature on circulating Hsp and anti-Hsp antibodies are
in many cases short on details about Hsp60 concentra-
tions, and about the specificity spectra of the antibodies,
their titers, and their true, direct, pathogenetic effects.
Thus, more studies are still needed to obtain a definitive
picture on these matters. Nevertheless, the information
already available indicates that the concurrence of
persistent CT infection and appearance of sf-Hsp60 can
promote an autoimmune aggression towards stressed
cells and the development of diseases such as autoim-
mune arthritis, multiple sclerosis, atherosclerosis, vasculi-
tis, diabetes, and thyroiditis, among others. At the same
time, immunocomplexes composed of anti-CT-Hsp60
antibodies and circulating Hsp60 (both CT and human)
may form deposits in several anatomical locations, e.g., at
the glomerular basal membrane. The opposite side of the
coin is that pre-tumor and tumor cells with sf-Hsp60 can
be destroyed with participation of the anti-Hsp60
antibody, thus stopping cancer progression before it is
even noticed by the patient or physician.
Hsp60, a Ubiquitous Molecule with Multiple Roles
in Health and Disease
Hsp60 is a Group I chaperonin highly conserved during
evolution with essential roles in cells and tissues [1–4]. In
eukaryotes, this chaperonin is usually described as a mitochondrial
molecule that works together with its co-chaperonin, Hsp10, to
assist in the correct folding of other mitochondrial proteins. The
two chaperonins assemble and form an ‘‘American football–
shaped’’ molecular complex, a structure that is efficient for
correctly folding other proteins, i.e., ‘‘client polypeptides’’ [5]. The
Hsp60/Hsp10 complex is typically formed of a double ring-shaped
Hsp60 oligomer of 14 monomers and a dome-shaped Hsp10 single
ring of seven monomers. Each Hsp60 monomer displays three
domains: apical, intermediate, and equatorial [6].
Mammalian Hsp60 has been well characterized [7] and, in
humans, its gene resides on Chromosome 2 [8]. Hsp60 proteins
are highly conserved in evolution and, therefore, those of
eukaryotes and prokaryotes share numerous identical amino acids
[2,7]. This high similarity in primary structure implies common
antigenic sites (henceforth called epitopes) that elicit and react with
crossreactive antibodies [9,10]. This is the reason why exogenous
Hsp60 from a microbe can elicit an immune response in humans,
a response that although directed primarily against the microbial
molecule also reacts with the endogenous chaperonin [11],
providing a link between infection and development of autoim-
mune diseases, as postulated for arthritis [12–14], multiple
sclerosis [15–17], and diabetes [9,18,19]. These findings have
stimulated interest in Hsp60 in physicians willing to understand
the molecular basis of disease. However, from the literature it
appears that research on circulating Hsp60 and anti-Hsp60
antibodies has been marred by a lack of rigorous quantification of
the chaperonin concentrations and antibody titers in plasma or
serum. Furthermore, the specificity spectrum of the anti-Hsp60
antibodies has not usually been determined and, therefore, it is
difficult if not impossible to know the range of antigens, namely
human and bacterial chaperonins, recognized by the antibodies
and with what avidity. Because of the two limitations mentioned
above, and because of the inherent difficulty in devising reliable
strategies to obtain direct correlations between antibody levels and
extension of pathological lesions and clinical status in represen-
tative samples of pathological specimens and patients and
adequate controls, conclusions about the role of anti-Hsp60
antibodies in the onset and progression of disease must be taken as
provisory and subject to challenge with further investigation. The
main aim of this review is to make pathologists and clinicians fully
aware of the existence and pathogenetic potential, which we
assume is quite high, of anti-Hsp60 antibodies, but at the same
time the review intends to raise awareness on the limitations of
previous studies and, thus, encourage new ones more quantitative
and accurate in terms of specificity and avidity of the antibodies.
In summary, this review presents a field with exciting prospects but
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in the past and what should be avoided in future research.
Surface and Secreted Hsp60 Can Activate the Immune
System
Although Hsp60 is primarily considered a mitochondrial protein,
in mammals 20% to 40% of cellular Hsp60 occurs in extra-
mitochondrial sites (Table 1) [20–23]. The presence of Hsp60 on the
cell membrane’s surface (sfHsp60) has been noted in normal [24],
stressed [25], and tumor cells [26–28] and was thought to be
associated with membrane transport and signaling [24,29]. An
increase in sfHsp60 levels is considered a danger signal for the
immune system in as much as it leads to activation and maturation of
dendritic cellsand generation ofanantitumor T cell response[27,30].
Hsp60 is a ligand of Toll-like receptor 4, part of the innate immune
system, and sfHsp60 expression positively correlates with the
triggering of apoptotic phenomena [31]. In addition, the expression
of sfHsp60 on the lymphocytic membrane has been associated with
spontaneous apoptosis and cell lysis [32,33]. Therefore, Hsp60
translocation through the plasma membrane should not be
considered just as a passive, inconsequential event, but as a key step
in the pathogenesis of immune system–mediated disorders (Table 2).
Hsp60 is also secreted from cells and thus reaches the interstitial
fluid and the bloodstream [34]. The levels of Hsp60 in plasma of
healthy subjects vary over a wide range from undetectable up to
over 1,000 ng/mL; nevertheless, plasma levels in any single
individual are rather stable, probably because they are under
genetic control [35]. Because of this individual stability of Hsp60
plasma levels when changes appear in any given person, they most
probably indicate that something is abnormal. This is one
important reason why circulating Hsp60 has recently become a
potentially useful marker for clinicians, worth measuring in sera of
patients affected by a variety of diseases, as will be discussed later.
However, due to the variations in Hsp60 levels among individuals,
quantification of circulating chaperonin in populations of patients
and controls must be carefully done and repeated to obtain
representative samples of data amenable to rigorous statistical
analysis that, in turn, will provide a satisfactory basis for assessing
correlations of Hsp60 levels with pathology.
Hsp60 Can Be Elevated in Tumors and Cardiovascular
Diseases
Previous studies have revealed that the levels of cytosolic Hsp60
in vivo gradually increase during carcinogenetic steps, from
normal tissue to dysplasia to fully developed carcinoma, in various
organs: uterine exocervix [36], large bowel [37], and prostate [38].
In contrast, in other malignancies cytosolic Hsp60 was found to
decrease during carcinogenesis as compared with normal tissue in
tumors of the tongue [39], bladder [40], and airways [41,42].
sfHsp60 occurs in the cell membrane of certain types of tumors
[28], where it is associated with p21ras protein [43] and also with
alpha-3-beta-1 integrin, which is involved in the adhesion of
metastaticbreastcancercellstolymphnodesand bonetissue[44].It
has also been shown that sfHsp60 plays a role in the metastatization
of pancreatic carcinoma [26]. sfHsp60 occurs on the membrane of
oral tumor cells and seemingly participates in the mechanism of the
tumor cell lysis induced by gammadelta T lymphocytes [45].
Experiments in vitro with a number of tumor cells have shown that
photodynamictherapycaninduceanincrease inHsp60[46,47] and
membrane surface localization [48].
In addition to carcinogenesis, Hsp60 has been associated with
several other pathologies, for example, with atherosclerosis (ATS),
a disease that can be serologically monitored by measuring Hsp60
and anti-Hsp60 antibodies [49]. It has been shown that soluble
Hsp60 plays a role in activating vascular and immune cells during
ATS development [49], and that the levels of complement-
activating anti-Hsp60 antibodies are elevated in ATS-related
diseases [50]. Hsp60 has been detected on the surface of stressed
endothelial cells [51,52] and, therefore, these cells become
susceptible to complement-dependent lysis by anti-Hsp60 anti-
bodies. In light of these findings, ATS has been proposed as an
‘‘autoimmune disease due to an immune reaction against Hsp60’’
[53]. Nevertheless, for the reasons mentioned earlier about
quantification of Hsp60 and anti-Hsp60 antibodies, one has to
be aware that the role of Hsp60 in ATS pathogenesis is still under
scrutiny. For example, while in teenagers a positive correlation
was revealed between early ATS and Hsp60 levels [54], the
picture is not clear in older individuals with symptomatic ATS,
because in these older patients there are so many other variables
that must be considered in relation to ATS that to make reliable
correlations between plasma Hsp60 levels and disease is
practically impossible.
Recently, it has also been shown that stressed myocardiocytes
excrete Hsp60 by the exosomal pathway [34], which may reflect
the increase in myocardial levels of Hsp60 that double by the end-
stage of heart failure [55]. A chronic injury of progressive heart
failure resulted from the localization of Hsp60 in the plasma
membrane [25]. Moreover, levels of sfHsp60 were positively
correlated with myocardiocyte apoptosis and with the release of
the chaperonin into circulation, resulting in the activation of the
innate immune system with generation of a pro-inflammatory
process in the myocardial interstitium [25].
Since sfHsp60 might be involved in the pathogenesis of ATS, by
extension one can infer that this chaperonin is implicated in the
pathogenesis of cerebrovascular disorders, such as stroke. In this
regard it is noteworthy that Hsp60 levels and distribution are
altered in various central nervous system conditions that are not
primarily due to the failure of blood circulation, such as
Alzheimer, Parkinson, and Huntington diseases, which suggests
a participation of the chaperonin in the pathogenesis of these
diseases unrelated to vascular pathology [56]. It has been shown
that Hsp60 expression in cultured human adult astrocytes is
induced by cytokines, i.e., interleukins IL-1b, IL-4, IL-6, and IL-
10, and TNF-alpha, which leads to the suggestion that Hsp60
plays an important role also in the pathogenesis of autoimmune
diseases of the nervous system, like multiple sclerosis [57].
Anti-Hsp60 antibodies have been found to occur in a number of
systemic autoimmune disease–associated vasculitides, such as
Takayasu arteritis, polyarteritis nodosa, Wegener granulomatosis,
and systemic lupus erythematosus [58]. In all of these conditions,
however, for the reasons mentioned earlier, the exact nature
(specificity) and role of the anti-Hsp60 antibodies in pathogenesis
is still incompletely understood.
Table 1. Hsp60 Locations and Functions.
Location Function(s) Reference
Mitochondrion Protein folding [5,6]
Cytosol Control of signal transduction, apoptosis,
senescence, glycolysis
[20–23]
Cell membrane Membrane transport, cell–cell signaling,
immune system alerting
[24–33]
Intercellular
interstitium
Either pro- or anti-inflammatory [25,49,50,59,61–63]
doi:10.1371/journal.ppat.1000552.t001
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Hsp60 has also been implicated in the pathogenesis of
degenerative joint diseases such as rheumatoid arthritis (RA)
[59]. This is an autoimmune disorder with pathogenesis and
outcome influenced by the balance between the activities of Th-1
and Th-2 cells. Th-1 activation induces secretion by RA synovial-
fluid mononuclear cells of pro-inflammatory cytokines such as IL-1
and TNF-alpha, with consequent cartilage damage, whereas Th-2
activation promotes secretion of IL-4, inhibiting Th-1 activity and
diminishing inflammation and cartilage damage [60]. In this
respect, it is interesting that mycobacterial Hsp60 activates Th-1
production of IL-1 and TNF-alpha, which suppress cartilage
proteoglycan synthesis and contribute to cartilage damage [61]. In
contrast, human Hsp60 stimulates Th-2 production of IL-4 and
determines a lower release of IL-1 and TNF-alpha by Th-1 cells in
comparison to non-human Hsp60-stimulated Th-1 cells [62]. It
has been postulated that a humoral response against bacterial
chaperonin can elicit a crossreaction against the infected host’s
Hsp60, thus perpetuating local inflammation and destructive
processes in cartilage [59,63]. All of these data, confirmed also in
experimental models of adjuvant arthritis [64], suggest that
human, but not bacterial, Hsp60 contributes to suppressing
inflammation. Unfortunately, the human chaperonin can also
serve as an autoantigen in pathological lesions that may attract
antibodies, thus contributing to inflammation and tissue destruc-
tion. Such considerations have to be taken into account when
thinking of therapeutic uses of Hsp60.
Under physiologic conditions, pancreatic beta-cells show Hsp60
only in mitochondria and secretory granules [65], but in
pancreatic islets affected by insulitis the chaperonin migrates
towards the cytoplasm as well as to the plasma membrane, in
which it can be detected by the immune system that, consequently,
mounts an immune response [66]. Since it was realized that Hsp60
is one of the most relevant self-antigens for diabetogenic T cell
clones, the chaperonin peptide DiaPep277 has been used to slow
down beta-cell damage after the clinical onset of diabetes, both in
non-obese diabetic mice and human adults [67,68]. The first
results seem encouraging, but further clinical trials are currently in
progress to complete the validation of this therapeutic approach.
It has also been hypothesized that Hsp60 plays a role in the
pathogenesis of thyroid and adrenal immune diseases characterized
by a proliferation of oncocytes, i.e., intensely eosinophilic cells with
granular cytoplasm and a very large number of mitochondria [69].
Lately, the chaperonin has been described as a relevant disease-
related autoantigen in autoimmune glomerulonephritis [70], juvenile
dermatomyositis [71], and both plaque and guttate psoriasis [72].
Microbial Hsp60, a Strong and Potentially
Harmful Antigen
Numerous infections caused by bacteria, fungi, and mycobac-
teria can trigger an immune reaction against the microbial Hsp60
with the generation of anti-Hsp60 antibodies [73]. In this regard, it
is important to bear in mind that anti-Hsp60 antibodies can also
be found in healthy subjects (likely elicited by the chaperonin from
microbes in the normal digestive tract flora for instance),
representing an early non-specific defense mechanism against
pathogens [10]. The sharing of considerable similarity in the
primary structure of microbial and host Hsp60 predicts antigenic
crossreactivity and development of immune reactions against both
proteins [11].
Humoral immune reactions to bacterial Hsp60, such as those
from Chlamydia pneumonia (CP) and Escherichia coli have been
suggested to be involved in the process of vascular endothelial
injury during ATS pathogenesis [74]. It has been stated that the
risk of crossreactivity between the microbial chaperonin and the
human counterpart on the surface of stressed cells of the arterial
endothelium is the cost the organism has to pay for protective
immunity against microbial molecules [75]. Infections by Porphyr-
omonas gingivalis[76–78] and Helicobacter pylori[79] have been
correlated with a higher risk of development of coronary ATS,
due to the high crossreactivity of anti-microbial Hsp60 antibodies
with human Hsp60. For similar reasons, E. coli Hsp60 has also
been implicated in the pathogenesis of autoimmune rheumatic
[80] and pancreatic [81] diseases, and Sjogren syndrome [82].
Moreover, an increase in the levels of autoantibodies against
endogenous Hsp60 precedes the onset of diabetes in cystic fibrosis
patients; hyperimmunization with bacterial Hsp60 caused an
increase in anti-Hsp60 autoantibodies that was followed by glucose
intolerance [83].
Chlamydia trachomatis Hsp60 Is Abundantly Produced
during Persistent Infections
Among pathogens, Chlamydia trachomatis (CT) is an intracellular
bacterium responsible for a sexually transmitted disease. Approx-
imately 4 million cases of CT infections are estimated to occur
annually in the United States, although only about one quarter of
those cases are diagnosed and treated [84].
CT includes three human biovars: trachoma (serovars A, B, and
Ba or C), urethritis (serovars D-K), and lymphogranuloma
venereum (LGV; serovars L1, 2, and 3) [85]. Each CT biovar
can cause from mild to severe symptoms. Some infected
individuals are asymptomatic, which allows spread from person
to person before the infection is detected. In the US in 1990, the
direct costs of treating CT infections and its complications were
estimated at US$4.2 billion [86], while projected costs for the
years 2000s were US$10 billion [87]. These figures clearly
demonstrate the magnitude of the health and social problems
caused by CT.
CT penetrates into epithelial cells as an elementary body and
then converts to a reticulate body, the replicating form of the
pathogen. During persistent infections, CT produces a large
quantity of Hsp60 (CT-Hsp60) [88], which has been implicated in
the pathogenesis of autoimmune disorders such as reactive arthritis
Table 2. Pathologic Conditions in Which Surface Hsp60 Has Been Correlated with Pathogenesis.
Condition Cell Role Reference
Cancer Tumor Involved in metastatization to lymph nodes and bones and antitumor immune response activation [26,44–48]
Atherosclerosis Endothelial Confers susceptibility to complement-dependent cell lysis [50–52]
Heart failure Myocardiocyte Promotes myocyte apoptosis and pro-inflammatory status in myocardium [25,34,53,55]
Diabetes Beta, (insulitis) Becomes target for T cell–mediated beta-cell destruction [66]
doi:10.1371/journal.ppat.1000552.t002
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tumor cells, which would contribute to female genital tract
oncogenesis [91,92].
There are three CT-Hsp60 isoforms: CT-Hsp60-1, mainly
found in the reticulate bodies, and CT-Hsp60-2 and CT-Hsp60-3,
which are released extracellularly [93]. Prolonged exposure of the
immune system to any of the CT-Hsp60 isoforms leads to immune
system activation and antibody formation [94]. CT-Hsp60 is able
to stimulate production of pro-inflammatory cytokines in endo-
thelial and smooth-muscle cells and macrophages [95], and it can
also promote the activation of specific immune cells via a Toll-like
receptor [96].
In a recent study, our group compared the amino acid
sequences of human-Hsp60 and CT-Hsp60-1 (serovar D), and
we found four epitopes with a 100% identity and 13 other peptides
of various lengths with identities between 33% and 75% [97].
These epitopes are present in all three domains of the molecule
(Figure 1).
Previous comparisons of human versus CT (serovars B, C, and
L2) Hsp60 sequences identified 13 major epitopes, seven of which
showed crossreactive antibody binding with homologous peptide
sequences in human Hsp60 [98]. These data should draw the
attention of clinicians towards an often ignored pathogenetic
factor, namely, the crossreactive anti-Hsp60 antibodies formed
during CT infection. One of the major objectives of this article is
to inform clinicians about the occurrence of these antibodies and
about their considerable pathogenetic potential.
Chlamydia trachomatis Infection and Antihuman-
Hsp60 Antibodies: Negative and Positive Impact
CT infections can persist for very long periods because, usually,
the human immune system cannot eliminate pathogens that
remain hidden but virulent at focal sites; thus, these silent foci
represent a high risk for complications [99].
People affected by CT develop high titres of serum antibodies
anti-CT-Hsp60 [93,99]. These antibodies also recognize homol-
ogous epitopes on human Hsp60 [100], so the more prolonged the
infection the greater the increase in the risk that crossreactive
antibodies will react against host cells expressing sfHsp60
(Figure 2). These examples illustrate the importance of assessing
the specificity spectrum of anti-Hsp60 antibodies as mentioned
earlier, to obtain a defined picture of the antibody populations at
play in pathology, a consideration that must also be applied when
considering CT versus CP infections (see below).
Eukaryotic Hsp60 is a ubiquitous, multifaceted, versatile
molecule in as much as it has been classically described in
mitochondria, but it has lately been found in extramitochondrial
sites [101]. In addition, during carcinogenesis Hsp60 may be
augmented or diminished [102]. If augmented, it can have either
pro- [103,104] or anti-apoptotic effects [23,105] or both [106].
Likewise, when Hsp60 is released outside cells, it can exert either
pro- [25,53] or anti-inflammatory roles [62].
High levels of Hsp60 in plasma of healthy subjects have been
positively correlated with low socioeconomic status, social
isolation, and psychological distress [107]. Moreover, serum levels
of Hsp60, but not those of anti-Hsp60 auto-antibodies, decline
with age [108]. These autoantibodies could bind Hsp60 and, thus,
produce immunoprecipitates with pathological impact on cells and
tissues. There is a report on one case of immune complex
glomerulonephritis in a 24-year-old individual with a CT infection
of the fallopian tube [109]. Cases like this are probably frequent
but missed in clinical practice. Therefore, the occurrence of anti-
Hsp60 autoantibodies in individuals with CT infections should
always be investigated, paying especial attention to aged patients,
since both prevalence of autoimmunity and titres of autoantibodies
tend to increase with age [110–113].
Anti-Hsp60 autoantibodies recognize Hsp60 epitopes exposed
on stressed endothelial cell membranes [51,52]. This would
represent the initial event triggering the formation of ATS lesions
Figure 1. Comparison between the structures of Chlamydia trachomatis (ct-) and human- (h-) Hsp60. Shown are the positions of the four
epitopes with 100% homologies. Circle: apical domain; arrow: intermediate domain; arrowhead: equatorial domain. See text and reference [94] for
further details. The images were created with PyMol (http://pymol.sourceforge.net).
doi:10.1371/journal.ppat.1000552.g001
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in cells of the vascular endothelium and to generate renal
vasculopathy in systemic lupus erythematosus [114].
When sfHsp60 is exposed on the myocardiocyte plasma
membrane, anti-Hsp60 autoantibodies can trigger myocyte
destruction via macrophage and/or neutrophil Fc recognition,
accelerating heart failure [25]. Studies on Hsp60 autoimmunity
also indicate that autoimmune diabetes can begin after bacterial
hyperimmunization [83].
Cautionary Notes on Anti-CT-Hsp60 Antibody
Measurements
Although several studies have been carried out to investigate the
presence of Hsp60 and anti-Hsp60 in CT-infected individuals (and
in various autoimmune diseases, as discussed elsewhere in this
article), the results must be subjected to scrutiny and, if possible, to
confirmatory research. This is pertinent, for example, to detection
of Hsp60 in human plasma.
First, in many of these studies, undiluted plasma was used to
measure Hsp60 or antibodies to Hsp60 by ELISA. As a consequence,
it becomes very difficult to be certain as to what was actually
detected by the antigen–antibody binding assay because undiluted
plasma is rich in a wide variety of proteins, which makes non-
specific binding likely. In addition, in a considerable number of
cases it is not clear what internal controls were used and how the
ELISA was calibrated to avoid false positives and false negatives.
Second, since antibodies to Hsp60 are also found in normal,
healthy individuals and since their levels could vary widely (see
above [35]), the possible significance of such antibodies, if they are
detected in patients, in regard to development of autoimmune
diseases can be very difficult to establish.
Third, despite the fact that antibodies to Hsp60 could be
induced by a variety of bacteria in human niches, including those
present in periodontal pockets and the gastrointestinal tract [10],
the antigenic specificity of the antibodies was not, as a rule,
determined. Thus, antibodies found to react with CT Hsp60 could
very well have been elicited by chaperonins from other microbes, a
possibility that must not be ignored due to the known high degree
of similarity of Hsp60 across species. Consequently, efforts must be
made to obtain and prepare panels of well-characterized antigens
Figure 2. Potential effects of anti-CT-Hsp60 antibodies generated during persistent CT infections. CT-Hsp60 is released from cells
infected with Chlamydia trachomatis (CT), and anti-CT-Hsp60 antibodies are produced by the host’s immune system. In turn, these antibodies
recognize surface Hsp60 on either stressed or tumor cells and, consequently, cell lysis and organ destruction can occur, determining pathogenesis of
a number of diseases (see text for further details). Likewise, immunocomplexes formed by anti-CT-Hsp60 antibodies and CT- (or human-, not shown)
Hsp60 can form deposits in the glomerular basal membrane, causing an idiopathic form of glomerulonephritis. Tumor cell lysis can arrest
tumorigenesis, in which case it is likely that the infected individual escapes from cancer without having experienced a detectable pathology or
symptom.
doi:10.1371/journal.ppat.1000552.g002
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those most likely to be the relevant ones for any bacterial infection,
including CT infection.
Finally, it is of the utmost importance to be aware that CP
infections are more widespread in the human population than are
CT infections [115]. More than half of all adults in North America
have antibodies to CP. As a consequence, one can expect that
antibodies to CP Hsp60, which are most likely directed against
similar epitopes as those in CT, should be of common occurrence.
Here again, the challenge is to determine the specificity spectrum
of the antibodies with a panel of Hsp60 molecules from pertinent
species and, thus, determine with accuracy the true specificity of
the antibodies as well as their titers with regard to the antigen
under investigation (e.g., CT or CP Hsp60).
How, and When, to Defend from CT-Hsp60 Production?
Despite all the suggestive information already in the literature,
sfHsp60 has not yet been sufficiently studied in human tissues under
normal or pathological conditions, or after stress when Hsp60
translocates to the plasma membrane. sfHsp60 becomes recogniz-
able by the immune system, leading to the generation of
autoantibodies and other manifestations of the immune response
accompanied by cell destruction, inflammation, and organ damage
(Table 3). This series of concatenated events typical of autoimmune
disorders due to autoantigens that share sequence homology with
human Hsp60 very likely occur in various diseases, for example,
Hashimoto disease, thyroiditis, scleroderma, pemphigoid, multiple
sclerosis, chronic active hepatitis, primary biliary cirrhosis, and
Addison disease [116]. It is imperative to ask the question whether
all those diseases, and perhaps others, are not due at least in part to
the invasion of the host by microbial Hsp60 from undiagnosed or
misdiagnosed (and therefore untreated) bacterial infections, among
which CT could be one of the prime suspects. The invading Hsp60
would elicit antibodies primarily directed to the microbial
chaperonin but crossreactive with the host’s counterpart (Figure 2).
If that were the case, an essential distinction should be made
between these antibodies elicited by a foreign antigen but reactive
also with autoantigens and true autoantibodies elicited by
autoantigens. This essential difference could very well mean other
important dissimilarities pertaining to structural, functional, and
biological molecular aspects, all of which deserve investigation in
order to understand pathogenetic mechanisms, and to devise
adequate diagnostic and therapeutic strategies.
On the other side of the coin, since sfHsp60 can be present on
the surface of tumor cells [26–28], the occurrence of an anti-
Hsp60 immune response, including circulating autoantibodies,
could be beneficial in as much as the response would have a strong
negative impact on tumor growth [117]. In this scenario, patients
with a chronic CT infection may inadvertently be protected from,
or ‘‘vaccinated’’ against as it were, cancer (Figure 2). This is a
plausible possibility deserving investigation, even more so because
a comprehensive study in vivo on sfHsp60 localization in tumor
cells is still lacking.
In regard to the above, in vitro experiments showed that
photodynamic therapy could induce sfHsp60 localization in a
number of tumor cells [48]. This is one reason why it is believed
that the presence of anti-Hsp60 autoantibodies might have
antitumor effects and that the use of such antibodies could be a
means for cancer treatment.
In summary, the high prevalence of CT infection in humans
and the high similarity in the primary structure of CT and human
Hsp60 should keep physicians on the alert and drive them to make
every possible effort to diagnose CT infection or rule it out. Thus,
measuring serum for anti-Hsp60, and also anti-Hsp10, antibodies
offers a promising approach if the proper methodology is used (as
discussed earlier in various sections of this article). If this diagnostic
conduct is abided by, it is likely that much light will be shed on a
number of misdiagnosed, idiopathic autoimmune disorders. In
addition, investigating autoimmunity elicited by CT Hsp60 could
provide information on a suspected protective role of the
autoimmune phenomena in cancer, specifically when the cancer
cells bear sfHsp60.
Conclusions and Perspectives
The chaperonin of Group I, Hsp60, or Cpn60 has many
important functions, and its alterations, whether genetic or
acquired, can cause pathologic disorders [118,119]. Like other
Hsp chaperones, Hsp60 is an evolutionarily conserved protein
and, consequently, molecules from different species share
sequences that can be antigenic and elicit crossreactive antibodies.
This situation is particularly relevant to human diseases with an
autoimmune mechanism, particularly in patients with chronic
infections.
This article focuses on the potential pathogenetic effect of
Hsp60 from Chlamydia trachomatis (CT-Hsp60) that shares various
antigenic determinants with the human counterpart. Infection
with CT leads to an immune response against the invader’s
chaperonin, but the response crossreacts with the host’s Hsp60.
The crossreactive effects are perpetuated, and possibly amplified,
Table 3. Anatomic Sites and Cells in Which Hsp60 Could Play the Role of Autoantigen during Persistent CT Infection and Anti-CT-
Hsp60 Antibody Production.
Site Cell Pathology Reference
Vessels Endothelial cells Vasculitis, atherosclerosis [49,50,53,54,58]
Heart Myocardiocyte Myocarditis, infarct, heart failure [25,34,55]
Joints Synoviocyte Rheumatoid arthritis [59,61–63]
Pancreas Beta-cells Diabetes [66,69]
Thyroid Thyreocyte Hashimoto thyroiditis [69]
Liver Hepatocyte, biliary duct cells Chronic active hepatitis, primary biliary cirrhosis [69]
Adrenal glands Glomerular zone cells Addison disease [69]
Kidney Glomerulus Glomerulonephitis [70]
Skin Keratinocyte, fibroblast, endothelial cells Scleroderma, pemphigoid, psoriasis, dermatomyositis [71,72]
doi:10.1371/journal.ppat.1000552.t003
PLoS Pathogens | www.plospathogens.org 6 August 2009 | Volume 5 | Issue 8 | e1000552by the fact that the human chaperonin is present not only inside
cells but also outside them, attached to the cell membrane or in
circulation. Thus, antibody-antigen reactions can occur on the
cell’s surface, in the intercellular space, and in biological fluids
with a variety of consequences, including modulation of the
immune system and generation of pathological lesions with
immunoprecipitates. If Hsp60 occurs on the surface of malignant
cells, a fact already ascertained for some types of cancer,
antibodies or immune cells that react with the chaperonin have
the potential ability to damage the tumor.
Since CT infections may go undetected or be misdiagnosed, and
may be long lasting, anti-Hsp60 antibodies are likely to be causing
disease silently for a long time without the physician being aware
of this potentially very damaging situation. Likewise, protracted
infections with CT could protect against the growth of certain
tumors. These examples demonstrate why Hsp60 is considered a
multifaceted, versatile molecule difficult to understand in any
particular situation. As a consequence, the physician ought to
become aware of the various roles of Hsp60 and anti-Hsp60
antibodies and of the importance of measuring them in all cases
with suspected or demonstrated autoimmune manifestations.
It would be important to determine at what stage of human
development Hsp60 begins to appear in extracellular locations and
whether it is tolerogenic. Elucidation of these aspects of Hsp60
biology is essential to determine if, why, and when anti-Hsp60
autoantibodies (elicited by the endogenous human chaperonin)
emerge, and what is their distribution in any given population.
Clarification of these points will help understand the mechanism
involved in the generation of anti-Hsp60 antibodies and/or their
increase in response to invasion by a crossreactive chaperonin
from a microbe.
Accession Numbers
The Entrez Protein Data Bank (http://www.ncbi.nlm.nih.gov/
sites/entrez?db=protein) accession codes for the proteins dis-
cussed in this paper are Chlamydia trachomatis Hsp60-1 (CAH04305,
[97]); mitochondrial heat shock 60 kD protein 1 variant 1 [Homo
sapiens] (ACE06961, [97]); mycobacterial Hsp60 (CAD95638,
[120]); Chlamydia pneumoniae Hsp60 (AAF38748, [121]); Escherichia
coli Hsp60 (Q1R3B6, [122]); Helicobacter pylori (ACD47477,
Reference Kersulyte, D., et al., direct submission, unpublished).
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